CliffBio
biologic

Rebyota

fecal microbiota, live-jslm

Loss of exclusivityNovember 2034FDA regulatory exclusivity expiry
CompanyFerring Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameRebyota
Active ingredientfecal microbiota, live-jslm
StrengthBETWEEN 1X10^8 AND 5X10^10CFU
Dosage formSuspension
RouteRectal
ModalityBiologic
FDA approvalNovember 2022
Marketing statusRx

More from Ferring Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Rebyota patent cliff — loss of exclusivity November 2034 | CliffBio